Join the Oncology Voice Network. Join for Free
Season 1, Episode 18: Challenges Facing the Pharma Universe with Jack West

Season 1, Episode 18: Challenges Facing the Pharma Universe with Jack West


Share This Article


In this episode of the Pharmaverse podcast, host Michael Pietrack interviews Jack West, the VP of Clinical Development at Summit Therapeutics. They discuss Jack's transition from being a practicing oncologist to working in the pharmaceutical industry, the importance of collaborations with pharma, and the challenges and rewards of working in a small pharma company. "Going into a pharma company is like riding a mechanical bull. The directions change frequently and sometimes you're not ready for them." Jack also shares his insights on leadership best practices and the top challenges facing the pharma industry. "Having well-defined roles and a clear value is important in leadership." The episode concludes with a discussion on Summit Therapeutics' recent positive press releases and Jack's social media presence.

📗 Takeaways:

🤝Collaborations with pharma can be instrumental in making the leap from clinical practice to the pharmaceutical industry.

💹Transitioning from clinical practice to pharma requires a willingness to adapt to new priorities and challenges.

🕴Leadership in the pharmaceutical industry requires well-defined roles, clear value, and a culture of open communication and dissent.

💊The pharma industry faces challenges such as evolving regulatory approvals, acceptance of data from different regions, and incorporating patient perspectives.

🐟Working in a small pharma company offers agility, involvement in various processes, and the opportunity to make a significant impact.

👐Stay open to new perspectives and be willing to modify your opinions based on new information.

🩺Adapt to the evolving regulatory landscape and consider the challenges of generalizing data from different regions.

🏥Recognize the changing role of patients in decision-making and incorporate their perspectives and priorities.

💉Embrace the opportunities for growth and learning in a small company environment.

💊Be bold, clarify your goals, and actively pursue your desired path. 

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
MSL Career Options: The transition from Field Medical to Medical Director
Partner Avatar MSL Talk: Tom Caravela, Josh Corriveau

MSL Career Options: The transition from Field Medical to Medical Director

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Article
External control arms in oncology: current use and future directions
OVN Avatar P.S. Mishra-Kalyani, L. Amiri Kordestani, D.R. Rivera, H. Singh, A. Ibrahim, R.A. DeClaro, Y. Shen, S. Tang, R. Sridhara, P.G. Kluetz, J. Concato, R. Pazdur, J.A. Beaver

External control arms in oncology: current use and future directions

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Explore OVN